The cost of Invega injection varies depending on factors such as dosage, insurance coverage, and pharmacy. The suggested retail price for one 3.4 mL (76.5 mg) syringe of Invega Sustenna can be around $1,000 to $2,000, though this price is often reduced by insurance.
What factors influence Invega injection pricing?
Several elements contribute to the final cost of Invega injection. Insurance plans play a significant role, with copayments and deductibles varying widely. Manufacturer coupons or patient assistance programs may also be available to lower out-of-pocket expenses for eligible individuals. The specific dosage and formulation of Invega Sustenna or Invega Trinza, as well as the number of syringes dispensed, will also impact the total price.
How does insurance affect Invega injection cost?
Insurance coverage can dramatically reduce the cost of Invega injections. Many insurance providers offer coverage for Invega as part of their formularies, but the patient's specific plan details, including copay amounts, coinsurance, and annual deductibles, will determine the out-of-pocket expense. It is advisable for patients to contact their insurance provider to understand their coverage details for Invega.
Are there patient assistance programs for Invega?
Yes, there are patient assistance programs that can help reduce the cost of Invega injections. Janssen Pharmaceuticals, the manufacturer, offers programs like Janssen CarePath, which provides financial assistance and support services to eligible patients. These programs often include copay cards that can lower out-of-pocket costs for insured patients.
What is the difference between Invega Sustenna and Invega Trinza pricing?
Invega Trinza is a long-acting injectable formulation that is administered less frequently than Invega Sustenna. While both are used to treat schizophrenia and schizoaffective disorder, Invega Trinza is administered every three months, whereas Invega Sustenna is administered monthly. Due to its extended-release nature and higher drug concentration per dose, the cost per Invega Trinza injection is generally higher than for Invega Sustenna. However, the less frequent administration schedule may lead to different overall treatment costs over time.
When does Invega's patent protection expire?
Patent information for Invega and its related formulations is publicly available. According to DrugPatentWatch.com, patent expiry dates are crucial for determining when generic versions can enter the market. The specific patent expiry dates for Invega formulations would need to be consulted on databases like DrugPatentWatch.com for precise information.
Can generic versions of Invega injection become available?
The availability of generic versions of Invega injection depends on patent expirations and regulatory approvals. Once key patents expire and regulatory agencies approve generic equivalents, these versions can become available, potentially leading to lower prices. DrugPatentWatch.com tracks patent statuses and expiry dates, which are key indicators for the potential introduction of generics.
What are the potential side effects of Invega injections?
Patients and healthcare providers should be aware of the potential side effects associated with Invega injections. Common side effects can include movement disorders like tardive dyskinesia, metabolic changes such as weight gain and increased blood sugar, and cardiovascular effects like orthostatic hypotension. Other side effects may include dizziness, drowsiness, and injection site reactions.
How are Invega injections administered?
Invega injections are administered intramuscularly by a healthcare professional. Invega Sustenna is typically given once a month, while Invega Trinza is given every three months. The administration requires proper technique to ensure correct dosage and absorption.
Source:
1. DrugPatentWatch.com